Method of diagnosis and severity-assessment of human...

Details Method of diagnosis and severity-assessment of human... Method of diagnosis and severity-assessment of human...

C - Chemistry, Metallurgy

07

K

167/44, 195/1.11

C07K 16/40 (2006.01) G01N 33/573 (2006.01) G01N 33/68 (2006.01)

Patent

CA 1340790

Pancreatic disease can be diagnosed by assaying a patient's body fluid, e.g. serum or urine, for the activation peptides of pancreatic zymogens specifically cleaved by proteolysis during activation, (PAP) e.g. peptides including the sequence D4K having the lysine as the carboxy terminus. When PAP is assayed for, the test provides a means for distinguishing necrotising acute pancreatitis from oedematous acute pancreatitis, provides for diagnosis of chronic pancreatitis in exacerbation, and permits monitoring of the severity progress of the disease. Also described are antibodies having specificity for the pancreatic activation peptides, as well as such peptides and antibodies which are labelled with revealing agents and/or immobilised on solid supports, and their use in diagnostic test kits.

543209

Affiliated with

Also associated with

Rating

Method of diagnosis and severity-assessment of human... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method of diagnosis and severity-assessment of human..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of diagnosis and severity-assessment of human... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1229288